# Tumor-informed and tumor-naive assay design

Source: https://onco.cc/terms/tumor-informed-assay-design/  
OnCo record `tumor-informed-assay-design` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some blood tests first learn which DNA changes to track from a tumor sample. Others look for predefined signals without requiring that tumor-specific starting information.

## Summary

Tumor-informed assays select features from a person's tumor; tumor-naive approaches use signals specified without that individual tumor profile. A primary breast cancer study compared several such assays on the same plasma samples and found method-dependent sensitivity at low concentrations. That comparison does not rank every commercial platform. Tissue availability, selected features, sampled molecules and intended clinical use all matter, while detection performance remains separate from evidence that acting on the result improves outcomes.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: tumour-informed ctDNA assays; tumor-informed versus tumor-naive; tumor-agnostic ctDNA assay design

## Sources

- Tumor-informed and tumor-naive assay comparison (2023): https://doi.org/10.15252/emmm.202216505

## Connected records

- terms: [Analytical versus clinical validation](https://onco.cc/terms/analytical-vs-clinical-validation/), [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Evidence from measurement to patient benefit](https://onco.cc/terms/measurement-to-benefit-evidence/), [Finite-molecule sampling in blood tests](https://onco.cc/terms/finite-molecule-sampling/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)

---
JSON: https://onco.cc/api/v1/entities/tumor-informed-assay-design.json